SAGA is a cancer diagnostics company featuring unique and proprietary technologies to quantify cancer in a simple blood test or other “liquid biopsy”.  SAGA’s non-invasive liquid biopsy tests measure the biomarker “circulating tumor DNA” and enables more precise monitoring of tumor size and spread, more accurate measurement of therapy response, and the critical information needed to decipher the DNA mutations that may be targetable with clinically-approved drugs or therapies currently in clinical trials.  The company has unique technologies offering an unprecedented level of accuracy and sensitivity (limit of detection to 0.001%), which in turn leads to the identification and matching of more patients to the most appropriate therapies, as well as improved patient outcomes through better and more timely patient follow-up.

SAGA Diagnostics

SAGA Diagnostics